June 4, 2021
Suzhou-based Intocare Medical Technology Co. Ltd. raised up to ¥100 million (US$15.66 million) in a series D funding round led by Qiming Venture Partners. Oriza Holdings, Oriza FOFs and Yuanbio Venture Capital also participated in the round. The company said the proceeds would be used for product R&D, clinical research, marketing promotion, and the launch of new offices and production sites.

Intocare bags $15.7M in series D to double down on its e-stapling solutions

China VC Weekly: Logistics, Robots and Surgical Instruments
(Source: Megarobo)
In last week’s VC news across China, logistics upstart YQNLink bags a whopping $100 million in its latest round, Hong Kong-based investment firm Gaw Capital Partners closes a further $430 million in funds, robotics startup MegaRobo closes a hefty $65 million investment round while Suzhou’s IntoCare Medical rakes in more than $15 million in its Series D fundraising round. Logistics startup YQNLink raises over $100 million in latest round
Digital container logistics platform YQNLink has raised $100 million from a group of venture capital investors. The company plans to use the proceeds of its latest fundraising round to hire and incentivize the best available talent. YQNLink also expects that the new funds will allow it to firmly establish an ‘ecosystem’ at the cost of short-term profits, according to founder and CEO Zhou Shihao. “The coronavirus crisis has brought more attention from society to the international logistics industry,” Zhou expressed. The company’s shareholders include major US investment firms such as Coatue, Sequoia Capital and DCM Ventures, as well as Chinese counterparts China Merchants Venture and Source Code Capital. Having served roughly 20,000 corporate clients, YQNLink is expected to handle 700,000 shipments this year backed by its offices in China, Japan, the US, Mexico, Brazil and several key markets in Southeast Asia. About YQNLink
Established in 2015, Shanghai-based YQNLink has expanded its business scope from online slot booking to providing shippers with one-stop services. In addition to container shipping, the company’s products also include air and rail freight, cross-border e-commerce transport, as well as trucking, customs clearance and storage services at both departure and arrival ports. Hong Kong’s Gaw Capital Partners close $430 million investment round
Hong Kong-headquartered Gaw Capital Partners announced on Friday the closing of its proptech-oriented Gaw Growth Equity Fund I, bringing the total amount raised in the endeavor to $430 million. Limited partners in the dealings include sovereign wealth funds, endowments and other institutional investors that have provided capital for previous Gaw undertakings, as well as new partners. “We are delighted to be closing Gaw Growth Equity Fund I successfully in such a short time,” said Christina Gaw, managing principal and co-chair of alternative investments for the family-led private equity firm. “The institutional investors’ commitments to our Gaw Growth Equity Fund I reflects their readiness to allocate more of their capital towards proptech and ESG related investments, given the attractive market opportunity and rapid growth of the sector.”
About Gaw Capital Partners
The investment firm backs high-growth, Asia-focused companies in proptech and operational businesses related to real estate. Since its founding in 2005, the company has raised six funds targeting Greater China and APAC. Gaw has raised $16.9 billion in equity since 2005 and had $27 billion in assets under management as of Q3 2020. Kai-Fu Lee backed AI robotics startup raises MegaRobo raises $65 million
MegaRobo, a high-tech startup focused on AI and robotics applications in life sciences and other sectors, has raised $65 million in a funding round led by Hong Kong-listed pharma giant WuXi AppTec, according to the company statement. The round was joined by existing investors including Matrix Partners China, Dr. Kai-Fu Lee’s Sinovation Ventures, Germany-based Bosch’s investment arm Bosch Venture Capital, early-stage investment firm Future Capital, Liando U Valley and Joy Capital – a consumption-driven investment firm that has backed startups like grocery app Nice Tuan, digital energy platform Newlink and artificial meat brand Starfield. MegaRobo had previously raised $30 million in a Series B round joined by Matrix Partners China, Joy Capital, Sinovation Ventures, Liando U Valley, and Bosch Venture Capital last year, followed by a similar-sized Series B+ round financing from Matrix Partners China, Sinovation Ventures and Joy Capital in February this year. Following the latest funding round, MegaRobo will continue to bankroll the R&D and innovation of automation products and business capacity. It will also advance the construction of its automatic robot laboratory, as stated in a company’s announcement. About MegaRobo
Established in 2016, the innovative company has served 112 clients and has delivered dozens of automatic systems and products such as motion control components, robots, megacloud platform, and robot laboratory system, according to the firm’s official website. Surgical instrument company IntoCare Medical closes 100 million yuan Series D round
Suzhou-based surgical instrument company IntoCare Medical has raised roughly 100 million yuan ($15.7 million) in its series D financing round led by Qiming Venture Partners. Investors including Oriza Holdings, Oriza Fund of Funds, and YuanBio Venture Capital also took part in the round. The medical technology company plans to use the fresh capital for product development, clinical research and marketing activities, as well as to open new offices and manufacturing sites. IntoCare’s products are currently available in markets across Europe, the Middle East, Africa, North America and elsewhere. The Jiangsu-based healthtech firm said it has also won multiple provincial procurement bids. “We believe that powered staplers will become an increasingly popular option for surgical doctors and gradually earn the mainstream position,” said William Hu, managing partner of Qiming Venture Partners. “IntoCare has established a structured R&D platform and commercialization plan, and has begun international expansion.”
About IntoCare
Founded in 2015, IntoCare focuses on the production and commercialization of surgical instruments. The company has also launched a range of powered stapling solutions, which help surgeons eliminate the variable grip force by using battery power to drive knife blades and staples.

China VC Weekly: Logistics, Robots and Surgical Instruments

News provided by
Share this article
Share this article
SUZHOU, China, May 26, 2021  /PRNewswire/ -- IntoCare Medical Technology (Suzhou) Co., Ltd. (hereinafter referred to as "IntoCare"), a global pioneer in Powered Surgical Staplers, today announced the completion of up to 100 million RMB round D financing. Qiming Venture Partners led the investment with participation from Oriza Holdings, Oriza FOFs and YuanBio Venture Capital. The proceeds will be used for product R&D, clinical research, marketing promotion, and the launch of new offices and production sites. 100 Million RMB Round D Financing (PRNewsfoto/Intocare Medical Technology)
Founded in 2015, IntoCare is a high-tech company focusing on the manufacturing and commercialization of innovative surgical instruments. The company is committed to becoming one of the most innovative and dynamic surgical instrument companies in China. With its precise and profound insights into clinical demands, IntoCare has been persistently innovating in surgical product development. The company name "IntoCare" derives from "Insight and Innovation to Caring". IntoCare is the first company globally that has launched a full range of intelligent powered stapling solutions. It is believed that its technical advantages in the powered stapling segment enable it to compete with Johnson & Johnson and Medtronic, the two medical device titans. IntoCare's founding team, R&D and technical teams have a strong background and extensive industry experience in well-known multinational companies. Since its inception in 2015, IntoCare started building three major product lines and a seven-year product plan. Over the past years, the company reached the below milestones:
In October 2018, IntoCare Medical obtained ISO13485 certification;
In March 2020, all products in IntoCare Powered Stapling Platform received the CE certificate;
In September 2020, IntoCare received the Class III registration and production certificate for Powered Circular Stapler from China's NMPA;
In May 2021, IntoCare received the Class III registration and production certificate for Powered Endoscopic Linear Cutting Stapler from NMPA. The completion of these milestones marks the launch of IntoCare Powered Stapling Solution in China and globally. The solution allows intelligent interaction between different types of staplers, bringing general GI, colorectal, and thoracic surgery marching into an intelligent and power-platformed era. It also marks China's stapler system has entered an era of intelligent powered control, contributing to the transformation towards a more intelligent medical devices industry. Staplers, as surgical instruments, are widely used in surgical operations. According to the report "2021-2026 Stapler Industry Supply and Demand Survey and Investment Opportunity Strategic Research Report" by Beijing Puhua Youce Information Consulting Co., Ltd., China's stapler market size has increased from 4.827 billion RMB in 2015 to 9.479 billion RMB in 2019, with a compound growth rate of 18%. It is predicted that China's stapler market demand will reach 19.058 billion RMB by 2024, with a compound growth rate of 15%(2019 – 2024). IntoCare continues to carry out technological innovation and product research and development. As of May 2021, IntoCare had applied for 277 patents, 117 of which had been authorized patents. Nearly 60% of the patent applications are for invention patents. With its strong R&D capabilities and the recognition of various regulatory certifications, IntoCare's products have been marketed and sold worldwide, covering major markets including Europe, the Middle East, Africa, North America, among others. The products have been highly recognized in top-ranking hospitals in China and have won multiple provincial procurement bids. Ms. Zhang Hui, CEO of IntoCare, said, "Since its inception, IntoCare has always been committed to helping doctors better serve patients in China and globally with excellent and innovative products. In the past six years, IntoCare, with its 'Made-in-China' products, has reversed the world's impression of Chinese surgical products. At present, the company's self-developed Powered Stapling Platform has been at the forefront of the world and has been unanimously recognized by the industry. In the future, IntoCare will continue to uphold the 'insight into demand' spirit and 'self-development and innovation' creeds, and provide more products with intelligence, safety, efficacy and efficiency to serve the doctors and patients, and become a leading world-class enterprise." Mr. William Hu, Managing Partner of Qiming Venture Partners, said: "Qiming Venture Partners started investing in IntoCare at an early stage. We have witnessed IntoCare's efforts and achievements in the powered stapling segment. IntoCare Powered Stapling Platform is now in a leading position on a global scale. We are excited to see that Chinese medtech companies can build products that can rival global titans in product design. We believe that powered staplers will become an increasingly popular option for surgical doctors and gradually earn the mainstream position. IntoCare has established a structured R&D platform and commercialization plan and has begun international expansion. We look forward to seeing more successes with the company." Mr. Li Huaijie, senior partner of Oriza, said: "IntoCare's founding team has an in-depth understanding of the powered stapler. Product development is expected to address a large market and benefits patients both in China and globally. IntoCare's craftsmanship enables it to build innovative products. We firmly believe that the company has the potential to become a leader in this field. Oriza and its GP, Qiming Venture Partners, jointly invested in this funding round, which is another successful practice of Oriza's concept of 'an outstanding fund management team in the spirit of discovering, support and companionship'. It is also another support in the investment of Oriza 's GP fund. I hope this cooperation will further enrich Oriza investment ecology. We will leverage our advantages in capital and industrial resources to provide continuous support for IntoCare." About Qiming Venture Partners
Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and San Francisco Bay Area. At present, Qiming Venture Partners manages nine US dollar funds and six RMB funds, with total management assets of US$5.9 billion. Since its establishment, it has focused on investing in outstanding companies in the early and growth stages of the industries such as TMT and Healthcare. Up to now, Qiming Venture Partners has invested in more than 380 fast-growing innovative companies, of which more than 130 are traded on the New York Stock Exchange, Nasdaq, Hong Kong Stock Exchange, Taiwan OTC, Shanghai Stock Exchange and Shenzhen Stock Exchange. More than 40 companies have become industry-recognized Unicorns and super Unicorns. About Oriza
Oriza is China's first market-oriented professional fund-of-fund management team, managing China's largest venture capital FOFs, with a fund under management exceeding RMB 25 billion, and a radiation asset scale expected to exceed RMB 150 billion, participating in 124 funds of 71 fund management teams, covering more than 2,600 companies. Oriza is committed to playing the pivotal role of FOFs in industrial development and resource aggregation, relying on a deep understanding and judgment of the industry, and focusing on the long-term development dividends of medical and health, as well as industrial upgrading and innovation opportunities driven by intelligence and digitalization. Oriza took the lead in establishing a complete fund of fund investment and management system in the industry, and created China's first real management team community. Oriza has been awarded the "Top 10 Funds in the Chinese Market" and "China's Best Venture Capital Government Guidance Fund" issued by the China Association of Limited Partners, Zero2IPO, China Investment Group, 21st Century Business Herald and other institutions for many years. ", "China's Best Limited Partner TOP10", "Best FOF (RMB) Management Institution" and other awards. About YuanBio Venture Capital
YuanBio Venture Capital is an investment institution focusing on the early and growth stage of the medical and healthcare field, based in BIOBAY, and business covering across China and the world. At present, the total RMB and USD funds under management are nearly 6 billion RMB. They have completed investments in more than 100 high-quality projects, mainly involving the creation of new drugs, innovative medical devices, diagnostics and precision medicine, and medical services. They have achieved substantial investment returns, and many It was selected as one of the top 10 venture capital funds in China's medical and health field, and the most active medical and health investment institution in China. Through focus and abundant industry resources, YuanBio Venture Capital is determined to develop into one of the most successful medical and pharmaceutical venture capital funds in China. SOURCE Intocare Medical Technology

IntoCare Medical Completes Up to 100 million RMB Round D Financing, Doubling Down on Powered Stapling Industry

Doubling Down on Powered Stapling Industry - PRNewswire
3h agoVenture CapitalprnewswireViews: 16
/PRNewswire/ -- IntoCare Medical Technology (Suzhou) Co., Ltd. (hereinafter referred to as "IntoCare"), a global pioneer in Powered Surgical Staplers, today... -

IntoCare Medical Completes Up to 100 million RMB Round D Financing,
Doubling Down on Powered Stapling Industry - PRNewswire

Intellasia East Asia News
26-May-2021 Intellasia |  PR Newswire Asia |  11:20 AM
SUZHOU, China, May 26, 2021 /PRNewswire/ -- IntoCare Medical Technology (Suzhou) Co., Ltd. (hereinafter referred to as "IntoCare"), a global pioneer in Powered Surgical Staplers, today announced the completion of up to 100 million RMB round D financing. Qiming Venture Partners led the investment with participation from Oriza Holdings, Oriza FOFs and YuanBio Venture Capital. 100 Million RMB Round D Financing
The proceeds will be used for product R&D, clinical research, marketing promotion, and the launch of new offices and production sites. Founded in 2015, IntoCare is a high-tech company focusing on the manufacturing and commercialization of innovative surgical instruments. The company is committed to becoming one of the most innovative and dynamic surgical instrument companies in China. With its precise and profound insights into clinical demands, IntoCare has been persistently innovating in surgical product development. The company name "IntoCare" derives from "Insight and Innovation to Caring". IntoCare is the first company globally that has launched a full range of intelligent powered stapling solutions. It is believed that its technical advantages in the powered stapling segment enable it to compete with Johnson & Johnson and Medtronic, the two medical device titans. IntoCare's founding team, R&D and technical teams have a strong background and extensive industry experience in well-known multinational companies. Since its inception in 2015, IntoCare started building three major product lines and a seven-year product plan. Over the past years, the company reached the below milestones:
In October 2018, IntoCare Medical obtained ISO13485 certification;
In March 2020, all products in IntoCare Powered Stapling Platform received the CE certificate;
In September 2020, IntoCare received the Class III registration and production certificate for Powered Circular Stapler from China's NMPA;
In May 2021, IntoCare received the Class III registration and production certificate for Powered Endoscopic Linear Cutting Stapler from NMPA. The completion of these milestones marks the launch of IntoCare Powered Stapling Solution in China and globally. The solution allows intelligent interaction between different types of staplers, bringing general GI, colorectal, and thoracic surgery marching into an intelligent and power-platformed era. It also marks China's stapler system has entered an era of intelligent powered control, contributing to the transformation towards a more intelligent medical devices industry. Staplers, as surgical instruments, are widely used in surgical operations. According to the report "2021-2026 Stapler Industry Supply and Demand Survey and Investment Opportunity Strategic Research Report" by Beijing Puhua Youce Information Consulting Co., Ltd., China's stapler market size has increased from 4.827 billion RMB in 2015 to 9.479 billion RMB in 2019, with a compound growth rate of 18%. It is predicted that China's stapler market demand will reach 19.058 billion RMB by 2024, with a compound growth rate of 15%(2019 – 2024). IntoCare continues to carry out technological innovation and product research and development. As of May 2021, IntoCare had applied for 277 patents, 117 of which had been authorized patents. Nearly 60% of the patent applications are for invention patents. With its strong R&D capabilities and the recognition of various regulatory certifications, IntoCare's products have been marketed and sold worldwide, covering major markets including Europe, the Middle East, Africa, North America, among others. The products have been highly recognized in top-ranking hospitals in China and have won multiple provincial procurement bids. Ms. Zhang Hui, CEO of IntoCare, said, "Since its inception, IntoCare has always been committed to helping doctors better serve patients in China and globally with excellent and innovative products. In the past six years, IntoCare, with its 'Made-in-China' products, has reversed the world's impression of Chinese surgical products. At present, the company's self-developed Powered Stapling Platform has been at the forefront of the world and has been unanimously recognized by the industry. In the future, IntoCare will continue to uphold the 'insight into demand' spirit and 'self-development and innovation' creeds, and provide more products with intelligence, safety, efficacy and efficiency to serve the doctors and patients, and become a leading world-class enterprise." Mr. William Hu, Managing Partner of Qiming Venture Partners, said: "Qiming Venture Partners started investing in IntoCare at an early stage. We have witnessed IntoCare's efforts and achievements in the powered stapling segment. IntoCare Powered Stapling Platform is now in a leading position on a global scale. We are excited to see that Chinese medtech companies can build products that can rival global titans in product design. We believe that powered staplers will become an increasingly popular option for surgical doctors and gradually earn the mainstream position. IntoCare has established a structured R&D platform and commercialization plan and has begun international expansion. We look forward to seeing more successes with the company." Mr. Li Huaijie, senior partner of Oriza, said: "IntoCare's founding team has an in-depth understanding of the powered stapler. Product development is expected to address a large market and benefits patients both in China and globally. IntoCare's craftsmanship enables it to build innovative products. We firmly believe that the company has the potential to become a leader in this field. Oriza and its GP, Qiming Venture Partners, jointly invested in this funding round, which is another successful practice of Oriza's concept of 'an outstanding fund management team in the spirit of discovering, support and companionship'. It is also another support in the investment of Oriza 's GP fund. I hope this cooperation will further enrich Oriza investment ecology. We will leverage our advantages in capital and industrial resources to provide continuous support for IntoCare." About Qiming Venture Partners
Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and San Francisco Bay Area. At present, Qiming Venture Partners manages nine US dollar funds and six RMB funds, with total management assets of US$5.9 billion. Since its establishment, it has focused on investing in outstanding companies in the early and growth stages of the industries such as TMT and Healthcare. Up to now, Qiming Venture Partners has invested in more than 380 fast-growing innovative companies, of which more than 130 are traded on the New York Stock Exchange, Nasdaq, Hong Kong Stock Exchange, Taiwan OTC, Shanghai Stock Exchange and Shenzhen Stock Exchange. More than 40 companies have become industry-recognized Unicorns and super Unicorns. About Oriza
Oriza is China's first market-oriented professional fund-of-fund management team, managing China's largest venture capital FOFs, with a fund under management exceeding RMB 25 billion, and a radiation asset scale expected to exceed RMB 150 billion, participating in 124 funds of 71 fund management teams, covering more than 2,600 companies. Oriza is committed to playing the pivotal role of FOFs in industrial development and resource aggregation, relying on a deep understanding and judgment of the industry, and focusing on the long-term development dividends of medical and health, as well as industrial upgrading and innovation opportunities driven by intelligence and digitalization. Oriza took the lead in establishing a complete fund of fund investment and management system in the industry, and created China's first real management team community. Oriza has been awarded the "Top 10 Funds in the Chinese Market" and "China's Best Venture Capital Government Guidance Fund" issued by the China Association of Limited Partners, Zero2IPO, China Investment Group, 21st Century Business Herald and other institutions for many years. ", "China's Best Limited Partner TOP10", "Best FOF (RMB) Management Institution" and other awards. About YuanBio Venture Capital
YuanBio Venture Capital is an investment institution focusing on the early and growth stage of the medical and healthcare field, based in BIOBAY, and business covering across China and the world. At present, the total RMB and USD funds under management are nearly 6 billion RMB. They have completed investments in more than 100 high-quality projects, mainly involving the creation of new drugs, innovative medical devices, diagnostics and precision medicine, and medical services. They have achieved substantial investment returns, and many It was selected as one of the top 10 venture capital funds in China's medical and health field, and the most active medical and health investment institution in China. Through focus and abundant industry resources, YuanBio Venture Capital is determined to develop into one of the most successful medical and pharmaceutical venture capital funds in China.

Series A

Series C

Series D

IntoCare manufactures various surgical devices. It focuses on the research, development, and production of surgical instruments. The company was founded in 2015 and is based in Suzhou, China.

Name	Hui Zhang
Work History
Title	Chief Executive Officer
Status	Current

Wells Fargo Success Story

Professional Services

Platform Overview

IntoCare

Executives

IntoCare Management Team

1 Team Member